Invivyd (IVVD) Competitors $0.47 -0.02 (-3.47%) (As of 12:57 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IVVD vs. DMAC, ZNTL, FATE, TNYA, ATAI, ACRS, ACRV, SOPH, MOLN, and LFVNShould you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include DiaMedica Therapeutics (DMAC), Zentalis Pharmaceuticals (ZNTL), Fate Therapeutics (FATE), Tenaya Therapeutics (TNYA), Atai Life Sciences (ATAI), Aclaris Therapeutics (ACRS), Acrivon Therapeutics (ACRV), SOPHiA GENETICS (SOPH), Molecular Partners (MOLN), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical products" industry. Invivyd vs. DiaMedica Therapeutics Zentalis Pharmaceuticals Fate Therapeutics Tenaya Therapeutics Atai Life Sciences Aclaris Therapeutics Acrivon Therapeutics SOPHiA GENETICS Molecular Partners LifeVantage Invivyd (NASDAQ:IVVD) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability. Which has stronger earnings & valuation, IVVD or DMAC? DiaMedica Therapeutics has lower revenue, but higher earnings than Invivyd. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvivyd$11.56M5.07-$198.64M-$1.96-0.25DiaMedica TherapeuticsN/AN/A-$19.38M-$0.56-9.29 Does the media prefer IVVD or DMAC? In the previous week, Invivyd had 5 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 7 mentions for Invivyd and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.58 beat Invivyd's score of 0.53 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility and risk, IVVD or DMAC? Invivyd has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Is IVVD or DMAC more profitable? DiaMedica Therapeutics' return on equity of -43.67% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets InvivydN/A -155.33% -114.88% DiaMedica Therapeutics N/A -43.67%-40.81% Do insiders and institutionals have more ownership in IVVD or DMAC? 70.4% of Invivyd shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 17.9% of Invivyd shares are owned by insiders. Comparatively, 7.2% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend IVVD or DMAC? Invivyd currently has a consensus price target of $7.89, suggesting a potential upside of 1,509.69%. DiaMedica Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 34.62%. Given Invivyd's stronger consensus rating and higher possible upside, analysts plainly believe Invivyd is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer IVVD or DMAC? DiaMedica Therapeutics received 78 more outperform votes than Invivyd when rated by MarketBeat users. However, 78.95% of users gave Invivyd an outperform vote while only 62.84% of users gave DiaMedica Therapeutics an outperform vote. CompanyUnderperformOutperformInvivydOutperform Votes1578.95% Underperform Votes421.05% DiaMedica TherapeuticsOutperform Votes9362.84% Underperform Votes5537.16% SummaryInvivyd beats DiaMedica Therapeutics on 10 of the 17 factors compared between the two stocks. Ad Huge AlertsUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Click here to see how this opportunity could transform your portfolio. Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVVD vs. The Competition Export to ExcelMetricInvivydBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.61M$2.98B$5.19B$9.32BDividend YieldN/A1.85%4.78%4.06%P/E Ratio-0.2546.24128.2217.54Price / Sales5.07420.891,259.00139.66Price / CashN/A182.1341.2237.95Price / Book0.303.924.884.92Net Income-$198.64M-$42.03M$119.69M$225.78M7 Day Performance-16.10%-3.37%16.64%-1.56%1 Month Performance-33.78%7.95%16.32%6.68%1 Year Performance-86.35%21.00%35.37%22.48% Invivyd Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVVDInvivyd3.7078 of 5 stars$0.47-3.5%$7.89+1,567.5%-69.9%$56.58M$11.56M-0.25100Gap UpDMACDiaMedica Therapeutics2.9903 of 5 stars$5.35-0.6%$7.00+30.8%+89.1%$228.77MN/A-9.6120Short Interest ↓News CoverageZNTLZentalis Pharmaceuticals2.5782 of 5 stars$3.21+3.9%$10.00+211.5%-78.7%$228.75MN/A-1.24160FATEFate Therapeutics3.7125 of 5 stars$2.01+9.6%$6.75+236.7%-37.7%$228.36M$13.45M-1.22550Short Interest ↑TNYATenaya Therapeutics3.9767 of 5 stars$2.84+3.3%$17.33+510.3%-32.2%$224.99MN/A-1.91110Analyst ForecastNews CoverageATAIAtai Life Sciences3.0279 of 5 stars$1.34-1.5%$9.00+571.6%+4.8%$224.86M$331,000.00-1.6883Positive NewsACRSAclaris Therapeutics3.7795 of 5 stars$3.14-2.5%$8.80+180.3%+222.8%$224.29M$31.25M-6.1986Positive NewsACRVAcrivon Therapeutics1.4082 of 5 stars$7.13+1.0%$23.67+231.9%+57.1%$222MN/A-2.6158SOPHSOPHiA GENETICS2.8722 of 5 stars$3.33+1.5%$6.50+95.2%-24.2%$217.72M$62.37M-3.01520Analyst ForecastGap UpMOLNMolecular Partners0.6884 of 5 stars$5.35-1.5%N/A+19.9%$215.80M$6.00M-2.53180News CoverageLFVNLifeVantage3.1965 of 5 stars$16.94+5.6%N/A+165.2%$212.17M$196.01M50.13260Positive News Related Companies and Tools Related Companies DMAC Competitors ZNTL Competitors FATE Competitors TNYA Competitors ATAI Competitors ACRS Competitors ACRV Competitors SOPH Competitors MOLN Competitors LFVN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IVVD) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
